Analyst Mark Massaro of BTIG reiterated a Buy rating on GeneDx Holdings (WGS – Research Report), boosting the price target to $115.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Mark Massaro’s rating is based on GeneDx Holdings’ impressive financial performance and growth prospects. The company delivered a strong fourth quarter with significant revenue growth, surpassing both internal and market expectations. Their achievement of GAAP profitability and adjusted net income of $17 million in Q4 demonstrates financial robustness, further bolstered by a 40% increase in share price following the earnings report.
Additionally, GeneDx’s strategy to focus on higher-margin exome and genome panels has resulted in improved gross margins and average selling prices. The company’s forward-looking guidance for 2025 reflects continued revenue and volume growth, along with strategic shifts that are expected to sustain profitability. With a strong balance sheet and targeted investments, Massaro sees upside potential, justifying the Buy rating and the increased price target to $115.
In another report released today, Craig-Hallum also reiterated a Buy rating on the stock with a $114.00 price target.
Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of WGS in relation to earlier this year.